Trinity Biotech, CGM

Trinity Biotech climbs after data for glucose monitoring device
Trinity Biotech (TRIB) stock gains on encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose monitoring ((CGM)) system. Read more here.
Trinity Biotech announces results from pre-pivotal trial for CGM system
Trinity Biotech (TRIB) announced results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring
Trinity Biotech announces breakthrough in CGM technology
DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for its innovative continuous glucose monitoring (CGM) system.
Trinity Biotech Shares Rise After Update on Next-Gen Blood-Sugar Monitoring Device
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes management that measures blood sugar levels in real time.
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.
What's Going On With Trinity Biotech Shares Tuesday?
Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...
Trinity Biotech faces US aid policy impact, PPP loan scrutiny
Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based diagnostic company with a market capitalization of $23.7 million and current trading price of $1.32, is evaluating the potential effects of a recent ...